The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) hit a new 52-week high and has $212.74 target or 59.00% above today’s $133.80 share price. The 6 months bullish chart indicates low risk for the $3.39 billion company. The 1-year high was reported on Oct, 7 by Barchart.com. If the $212.74 price target is reached, the company will be worth $2.00B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 135,008 shares traded hands. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has risen 233.58% since March 4, 2016 and is uptrending. It has outperformed by 225.54% the S&P500.
Analysts await GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to report earnings on December, 5. They expect $-1.59 EPS, down 87.06% or $0.74 from last year’s $-0.85 per share. After $-0.73 actual EPS reported by GW Pharmaceuticals PLC- ADR for the previous quarter, Wall Street now forecasts 117.81% negative EPS growth.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) Ratings Coverage
Out of 7 analysts covering GW Pharmaceuticals (NASDAQ:GWPH), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. $182 is the highest target while $129 is the lowest. The $150.20 average target is 12.26% above today’s ($133.8) stock price. GW Pharmaceuticals has been the topic of 9 analyst reports since August 13, 2015 according to StockzIntelligence Inc. As per Monday, March 14, the company rating was maintained by Roth Capital. The stock of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) earned “Buy” rating by Cantor Fitzgerald on Monday, September 26. The firm earned “Buy” rating on Monday, November 30 by TH Capital. As per Friday, August 26, the company rating was upgraded by Numis Securities. Morgan Stanley initiated GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) on Thursday, August 13 with “Overweight” rating. The rating was initiated by Cantor Fitzgerald with “Buy” on Friday, June 3. The firm has “Sell” rating by Janney Capital given on Monday, June 27. The firm has “Buy” rating by Roth Capital given on Monday, November 30.
According to Zacks Investment Research, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.”
More important recent GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on April 27, 2013, also Investorplace.com published article titled: “GW Pharmaceuticals PLC- ADR Is a First-Rate Marijuana Stock (GWPH)”, Investorplace.com published: “GW Pharmaceuticals PLC- ADR (GWPH) Boards the Buyout Rumor Mill” on September 07, 2016. More interesting news about GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) was released by: Marketwatch.com and their article: “GW Pharmaceuticals PLC ADR” with publication date: May 08, 2013.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.